66. (new) A composition comprising at least one of the following E1 and E2 peptides:

E1-31 (SEQ ID NO:56) in the region consisting of amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) in the region consisting of amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) in the region consisting of amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) in the region consisting of amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) in the region consisting of amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO:66) in the region consisting of amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) in the region consisting of amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) in the region consisting of amino acids 325 to 344 of the E1 region,

Env 67 or E2-67 (SEQ ID NO:72) in the region consisting of amino acid positions 397 to 418 of the E2 region (epitope A),

Env 69 or E2-69 (SEQ ID NO:73) in the region consisting of amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) in the region consisting of amino acid positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) in the region consisting of amino acid positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) in the region consisting of amino acid positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) in the region consisting of amino acid positions 547 to 566 of the E2 region (epitope D), and

Env 13B or E2-13B (SEQ ID NO:82) in the region consisting of amino acid positions 523 to 542 of the E2 region (epitope C),

and optionally a pharmaceutically acceptable adjuvant.

67. (new) A composition comprising an E1/E2 complex formed from purified recombinant HCV single or specific oligomeric recombinant E1 or E2 proteins, said E1 protein having been purified to at least 80% pure, and said E2 protein having been purified to at least 80% pure; and optionally a pharmaceutically acceptable adjuvant.

68. (new) A composition comprising at least one purified recombinant HCV single or specific oligomeric recombinant envelope protein selected from the group

consisting of an E1 protein and an E2 protein, said E1 protein and E2 protein having been purified to at least 80% pure; and optionally a pharmaceutically acceptable adjuvant.

69. (new) A therapeutic composition for inducing an HCV-specific immune response comprising a therapeutic effective amount of a composition comprising at least one purified recombinant HCV envelope protein selected from the group consisting of an E1 protein and an E2 protein, said E1 protein and E2 protein having been purified to at least 80% pure; and optionally a pharmaceutically acceptable adjuvant.

70. (new) A therapeutic composition for inducing an HCV-specific immune response comprising a therapeutic effective amount of a composition comprising at least one of the E1 and E2 peptides according to claim 66; and optionally a pharmaceutically acceptable adjuvant.

71. (new) A therapeutic composition for inducing an HCV-specific immune response comprising a therapeutic effective amount of a composition comprising an E1/E2 complex formed from purified recombinant HCV single or specific oligomeric recombinant E1 or E2 proteins, said E1 protein having been purified to at least 80% pure, and said E2 protein having been purified to at least 80% pure; and optionally a pharmaceutically acceptable adjuvant.

72. (new) A therapeutic composition for inducing an HCV-specific immune response comprising a therapeutic effective amount of a composition comprising at least one purified recombinant HCV single or specific oligomeric recombinant envelope protein selected from the group consisting of an E1 protein and an E2 protein, said E1 protein and E2 protein having been purified to at least 80% pure; and optionally a pharmaceutically acceptable adjuvant.

73. (new) A composition according to any of claims 65, 67-69, 71 or 72 wherein said recombinant HCV envelope proteins are produced by recombinant mammalian cells.

74. (new) A composition according to any of claims 65, 67-69, 71 or 72 wherein said recombinant HCV envelope proteins are produced by recombinant yeast cells.

75. (new) A method of treating a mammal infected with HCV comprising administering an effective amount of a composition according to any one of claims 65-72 and, optionally, a pharmaceutically acceptable adjuvant.

76. (new) The method of claim 75 wherein said mammal is a human.--